# US 2019/0315766 A1 · Heterocyclic compounds as rsv inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315766 A1
- Document ID: US20190315766A1
- Status: Published application
- Kind: A1
- Application number: 16/379,881
- Filed: 2019-04-10
- Published: 2019-10-17
- Earliest claimed: 2018-04-11
- Assignees: Enanta Pharmaceuticals, Inc.
- Applicants: Enanta Pharmaceuticals, Inc.
- Inventors: Jianming Yu; Solymar Negretti-Emmanuelli; In Jong Kim; Yat Sun Or
- Web page: https://patentgrep.com/patent/US20190315766A1

## CPC

- C07D 495/14: Ortho-condensed systems
- A61P 31/16: for influenza or rhinoviruses
- C07D 413/14: containing three or more hetero rings
- C07D 493/10: Spiro-condensed systems
- C07D 493/14: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

## Claims

### Claim 1

A compound represented by Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
is optionally substituted aryl or optionally substituted heteroaryl;
is aryl or heteroaryl, which, when possible, is optionally substituted with one or more substituents which are not R2;
X is O, S or NR4, and Y is N or CR5; or X is N or CR5, and Y is O, S or NR4;
One Z is CR3, the other Zs are each independently selected from N and CR3;
Each R1 selected from the group consisting of: halogen, hydroxyl, protected hydroxyl, amino, protected amino, optionally substituted —C1-C8 alkyl, and optionally substituted —C1-C8 alkoxy;
Each R2 is selected from the group consisting of:
1) halogen;
2) optionally substituted —C1-C8 alkoxy;
3) optionally substituted —C1-C8 alkyl;
4) optionally substituted —C2-C8 alkenyl;
5) optionally substituted —C2-C8 alkynyl;
6) optionally substituted —C3-C12 cycloalkyl;
7) optionally substituted —C3-C12 cycloalkenyl;
8) optionally substituted 3- to 12-membered heterocycloalkyl;
9) optionally substituted aryl;
10) optionally substituted heteroaryl;
11) optionally substituted arylalkyl;
12) optionally substituted aryloxy;
13) —C(O)R12;
14) —C(O)NR13R14;
15) —C(O)NR11S(O)2R12;
16) —S(O)2NR13R14;
17) —NR13R14;
18) —NR11S(O)2R12;
19) —NR11C(O)R12;
20) —NR11C(O)NR13R14; and
21) —NR11C(O)NHS(O)2R12;
n is 0, 1, 2, 3 or 4;
m is 0, 1, 2, or 3;
R3 is selected from the group consisting of: hydrogen, halogen, cyano, nitro, hydroxyl, protected hydroxyl, amino, protected amino, optionally substituted —C1-C8 alkyl, and optionally substituted —C1-C8 alkoxy;
R4 is hydrogen or optionally substituted —C1-C8 alkyl;
R5 is hydrogen, halogen, optionally substituted —C1-C8 alkyl, or optionally substituted —C1-C8 alkoxy;
R12 at each occurrence is independently selected from the group consisting of:
1) Hydrogen;
2) Halogen;
3) Hydroxyl;
4) optionally substituted —C1-C8 alkoxy;
5) optionally substituted —C1-C8 alkyl;
6) optionally substituted —C2-C8 alkenyl;
7) optionally substituted —C2-C8 alkynyl;
8) optionally substituted —C3-C8 cycloalkyl;
9) optionally substituted —C3-C8 cycloalkenyl;
10) optionally substituted 3- to 8-membered heterocycloalkyl;
11) optionally substituted aryl;
12) optionally substituted arylalkyl;
13) optionally substituted heteroaryl; and
14) optionally substituted heteroarylalkyl;
R11, R13 and R14 are each independently selected from hydrogen, optionally substituted —C1-C8-alkyl, optionally substituted —C2-C8-alkenyl, optionally substituted —C2-C8-alkynyl; optionally substituted —C3-C8-cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; alternatively, R13 and R14 are taken together with the nitrogen atom they attached to form a heterocyclic ring.

### Claim 2 (depends on 1)

The compound of claim 1, wherein is one of the following by removal of a hydrogen atom:
wherein each of the above is optionally substituted when possible.

### Claim 3 (depends on 1)

The compound of claim 1, wherein is selected from one of the following groups by removal of one hydrogen atom, wherein each of the groups is optionally substituted:

### Claim 4 (depends on 1)

The compound of claim 1, wherein R2 is selected from one of the following groups, wherein each of the groups is optionally substituted:

### Claim 5 (depends on 1)

The compound of claim 1, represented by one of Formulas (IIa)˜(IIe), or a pharmaceutically acceptable salt thereof:
wherein R3′ is selected from the group consisting of: halogen, cyano, nitro, hydroxyl, protected hydroxyl, amino, protected amino, optionally substituted —C1-C8 alkyl, and optionally substituted —C1-C8 alkoxy; v is 0, 1, 2 or 3; , , X, Y, R1, R2, m, and n are as defined in claim 1.

### Claim 6 (depends on 1)

The compound of claim 1, represented by one of Formulas (IIIa)˜(IIId), or a pharmaceutically acceptable salt thereof:
wherein , , R1, R2, R5, n, m, and Z are as defined in claim 1.

### Claim 7 (depends on 1)

The compound of claim 1, represented by one of Formulas (IVa)˜(IVh), or a pharmaceutically acceptable salt thereof:
wherein m1 is 0, 1, 2, 3 or 4; m2 is 0, 1 or 2; each R21 is independently selected from halogen, —NH2, optionally substituted —C1-C3 alkyl, and optionally substituted —C1-C3 alkoxy; each R22 is independently selected from hydrogen and —CH3; each R23 is independently selected from hydrogen, halogen, —NH2, optionally substituted —C1-C3 alkyl, and optionally substituted —C1-C3 alkoxy; , X, Y, Z, R1, R2, m, and n are as defined in claim 1.

### Claim 8 (depends on 1)

The compound of claim 1, represented by one of Formulas (Va-1)˜(Va-5), or Formulas (Vb-1)˜(Vb-5), or a pharmaceutically acceptable salt thereof:
wherein m′ is 0, 1, or 2; R3′ is selected from the group consisting of: halogen, cyano, nitro, hydroxyl, protected hydroxyl, amino, protected amino, optionally substituted —C1-C8 alkyl, and optionally substituted —C1-C8 alkoxy; v is 0, 1, 2 or 3; , X, Y, R1, R2, and n are as defined in claim 1.

### Claim 9 (depends on 1)

The compound of claim 1, represented by one of Formulas (VI-1)˜(VI-2), or a pharmaceutically acceptable salt thereof:
wherein m′ is 0, 1, or 2; R3′ is selected from the group consisting of: halogen, cyano, nitro, hydroxyl, protected hydroxyl, amino, protected amino, optionally substituted —C1-C8 alkyl, and optionally substituted —C1-C8 alkoxy; v is 0, 1, 2 or 3; and , X, Y, R1, R2, and n are as defined in claim 1.

### Claim 10 (depends on 1)

The compound of claim 1, selected from the compounds set forth below or a pharmaceutically acceptable salt thereof:
Compound
Structure
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 12 (depends on 1)

A method of treating or preventing an RSV infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a combination of compounds of claim 1.

### Claim 13 (depends on 12)

The method of claim 12, further comprising the step of administering to the subject an additional anti-RSV agent.

### Claim 14 (depends on 12)

The method of claim 12, further comprising administering to the subject a steroid anti-inflammatory compound.

### Claim 15 (depends on 1)

A method of treating RSV and influenza in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 1, and a therapeutically effective amount of an anti-influenza agent.

### Claim 16 (depends on 13)

The method of claim 13, wherein the compound and the additional anti-RSV agent are co-formulated.

### Claim 17 (depends on 13)

The method of claim 13, wherein the compound and the additional anti-RSV agent are co-administered.

### Claim 18 (depends on 13)

The method of claim 13, wherein the additional anti-RSV agent is administered at a lower dose or frequency compared to the therapeutically effective dose of the additional anti-RSV agent when administered alone.
